Evidence map›Paper›PMID 37954076›Full record

ArticleFrontiers in oncology2023

Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy.

Georgina E Wood, Christopher P Bunting, Mesel Veli, Rupali Arora, Daniel M Berney, Constantine Alifrangis, Nicola D MacDonald, Rowan E Miller, Jonathan Shamash, Sara Stoneham and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Georgina E Wood *Medical Oncology, University College London Hospital, London, United Kingdom.
Christopher P Bunting *Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Mesel VeliMedical Oncology, University College London Hospital, London, United Kingdom.
Rupali AroraHistopathology, University College London Hospital, London, United Kingdom.
Daniel M BerneyHistopathology, Barts Health NHS Trust, London, United Kingdom.
Constantine AlifrangisMedical Oncology, University College London Hospital, London, United Kingdom.
Nicola D MacDonaldDepartment of Gynaecology, University College London Hospital, London, United Kingdom.
Rowan E MillerMedical Oncology, University College London Hospital, London, United Kingdom.
Jonathan ShamashMedical Oncology, Barts Health NHS Trust, London, United Kingdom.
Sara StonehamPaediatric Oncology, University College London Hospital, London, United Kingdom.
Michelle LockleyMedical Oncology, University College London Hospital, London, United Kingdom.
University College London · GBBarts Health NHS Trust · GBQueen Mary University of London · GBUniversity College Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant germ cell tumours are a group of rare cancers whose incidence peaks in late adolescence and early adulthood. Dysgerminomas of the ovary and seminomas of the testis are analogous diseases, but seminomas have a 10-fold higher incidence. The two tumours are morphologically identical and are only differentiated by surrounding organ-specific tissue or testicular germ cell neoplasia

Indexed as

carboplatinde-escalating chemotherapydysgerminomagerm cell tumoursseminomasystemic chemotherapy

Identifiers

PMID37954076
PMCPMC10634240
OpenAlexW4388265426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.